Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836859 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
A Phase 1 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03836859 is a Phase 1 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 30 participants.
The verdict
NCT03836859, a Phase 1 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and tolerability of a single short-term and a multiple dose scheme of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity. The secondary objective of this study is to assess the pharmacokinetics of single and multiple doses of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity.
Interventions
- OTHER Placebo
- DRUG rhNGF 20μg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836859
The ClinicalTrials.gov registry entry for NCT03836859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03836859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03836859 about?
NCT03836859 is a clinical study titled "Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers". The primary objective of this study is to assess the safety and tolerability of a single short-term and a multiple dose scheme of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity. The secondary objective of this study is to assess the pharmacokinetics of single and mul...
What is the current status of trial NCT03836859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-03-30. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT03836859?
The interventions under investigation include: Placebo (OTHER), rhNGF 20μg/mL (DRUG).
Who is sponsoring clinical trial NCT03836859?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.